Peter Attia MD357 ‒ A new era of longevity science: models of aging, rapamycin trials, biological clocks, & more
At a glance
WHAT IT’S REALLY ABOUT
Brian Kennedy and Peter Attia on aging models, rapamycin, clocks, supplements
- Kennedy argues that aging is best understood as a network losing resilience, with the hallmarks of aging being outputs rather than independent causes, and he points to mTOR and chronic inflammation as central drivers.
- He describes a model in which damage accumulates linearly while the barriers to failure states shrink, and says most current interventions only improve the oscillating component, adding perhaps five to ten years of healthspan without changing maximum lifespan.
- Kennedy describes his Singapore human trials of rapamycin and time-release AKG and his mouse work on urolithin A, spermidine and others, while he and Attia debate whether six-month trials can show real geroprotection.
- He presents a clinical-chemistry biological age clock built on NHANES data that he says predicts mortality better than chronologic age or methylation clocks, and he is skeptical of consumer epigenetic tests.
- Both speakers urge caution about stacking many interventions or using poorly proven clinic treatments, while Kennedy calls for more funding for basic aging science and sees AI as a growing tool for the field.
IDEAS WORTH REMEMBERING
5 ideasAging may be a loss of network resilience rather than 12 separate problems
Kennedy says the hallmarks are interconnected outputs of a homeostatic network, so fixing each one individually will not stop aging.
Current interventions may only work around the edges
Kennedy suggests that damage accumulates linearly and that most interventions affect the oscillating component, likely giving five to ten years of healthspan but not extending maximum lifespan.
Rapamycin is the best-supported small molecule but probably has a modest effect
Kennedy calls rapamycin the current gold standard for evidence, but expects a modest effect size in humans, not a change in the slope of aging.
Epigenetic clocks show association, not proven causation
Kennedy notes that proteomic, microbiome and facial clocks perform about as well as methylation clocks, that some first-generation methylation clocks predict mortality worse than age, and that consumer tests are unreliable.
A clinical chemistry clock may be more actionable than methylation clocks
Kennedy says a clock built from routine blood markers outperformed other predictors of mortality in NHANES and can flag risk even when no single value is out of range.
WORDS WORTH SAVING
5 quotesResilience is the most important term in aging and nobody understands it.
— Brian Kennedy
The idea that aging is 12 different things and you just need to fix all 12 of them is completely wrong.
— Brian Kennedy
If you're mixing 20 colors of or taking 20 pills, it's like mixing 20 colors of paint together. You're gonna get some ugly gray outcome.
— Brian Kennedy
It used to be that yeast and worms and flies were the model organisms for aging research, and now billionaires are the model organisms 'cause they're doing all kinds of stuff I can't even test.
— Brian Kennedy
If anybody tells you they have the answers to that, they're lying to you or they're lying to themselves, okay? We don't know.
— Brian Kennedy
High quality AI-generated summary created from speaker-labeled transcript.
